Nucleus Genomics

Nucleus Genomics

Nucleus Genomics operates as a consumer genetics company headquartered in Palo Alto and New York, selling into the elective IVF market. The firm's branding evokes a family office's generational planning ethos, but its website describes a clinical-facing technology product — at-home genetic tests for couples and embryo polygenic risk scoring for traits from diabetes and cancer to height and intelligence. The company trademark is 'Nucleus Genomics, Inc.', suggesting a corporate rather than partnership structure, and no public disclosures reference a founder's family wealth or a multi-asset investment program. The product suite divides into Health, Preview, Embryo, and IVF+ tiers. Health and Preview sell directly to consumers as a couple's planning tool, while Embryo and IVF+ route through fertility clinics to augment embryo selection during IVF cycles. The company claims 165+ clinics globally trust its test, naming Beverly Hills Fertility and Neway Fertility as partners. Its research arm, Nucleus Labs, released a paper on 'Origin', a family of nine genetic optimization models it describes as the most predictive ever built for human longevity from embryo DNA. The firm's geographic footprint spans the United States and Mexico, where it announced its first international expansion, though the website footer lists 'Supported countries' without further detail. No public AUM, fund structure, or investment vehicle is associated with the entity. The firm does not disclose a wealth-origin narrative, a management company, or a portfolio of third-party investments. Team pages beyond Dr. Nathan Treff and Genetic Reproductive Counselor Lila Dayani are not publicly enumerated. Recent operational activity indicates the firm is scaling a clinical network and consumer brand rather than deploying capital: it onboarded Neway Fertility and pushed into Mexico as its first international market, framing both moves as clinic partnerships within its IVF+ network. Structurally, Nucleus Genomics is a product company — not an asset allocator. The Altss database captured it under a 'Ventures' slug, but no evidence supports a venture investment program or a family-office mandate. The entity's distinctive architecture is its dual-path model: consumer revenue from at-home testing plus clinical revenue from IVF clinics paying for embryo analysis. Governance and succession risk reside in the founder's dual role as public scientific face and sole named executive, while compliance with HIPAA and state-level genetic privacy laws anchors its regulatory posture.